Overview

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Radboud University
Collaborator:
Dutch Cancer Society